hrcak mascot   Srce   HID

Izvorni znanstveni članak
https://doi.org/10.20471/acc.2017.56.04.22

Serum Osteoprotegerin in Patients with Calcified Aortic Valve Stenosis in Relation to Heart Failure

Sandra Makarović ; Clinical Department of Cardiovascular Disease, Osijek University Hospital Centre, School of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Zorin Makarović ; Clinical Department of Cardiovascular Disease, Osijek University Hospital Centre, School of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Ines Bilić-Ćurčić ; Clinical Department of Diabetes, Endocrinology and Metabolism Disorders, Osijek University Hospital Centre, School of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Jasminka Milas-Ahić ; Clinical Department of Immunology and Allergology, Osijek University Hospital Centre, School of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Ivan Mihaljević ; Clinical Department of Nuclear Medicine and Radiation Protection, Osijek University Hospital Centre, School of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Maja Franceschi ; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Centre, School of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Tomislav Jukić ; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Centre, School of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia

Puni tekst: engleski, pdf (948 KB) str. 733-741 preuzimanja: 265* citiraj
APA 6th Edition
Makarović, S., Makarović, Z., Bilić-Ćurčić, I., Milas-Ahić, J., Mihaljević, I., Franceschi, M. i Jukić, T. (2017). Serum Osteoprotegerin in Patients with Calcified Aortic Valve Stenosis in Relation to Heart Failure. Acta clinica Croatica, 56 (4), 733-741. https://doi.org/10.20471/acc.2017.56.04.22
MLA 8th Edition
Makarović, Sandra, et al. "Serum Osteoprotegerin in Patients with Calcified Aortic Valve Stenosis in Relation to Heart Failure." Acta clinica Croatica, vol. 56, br. 4, 2017, str. 733-741. https://doi.org/10.20471/acc.2017.56.04.22. Citirano 27.11.2020.
Chicago 17th Edition
Makarović, Sandra, Zorin Makarović, Ines Bilić-Ćurčić, Jasminka Milas-Ahić, Ivan Mihaljević, Maja Franceschi i Tomislav Jukić. "Serum Osteoprotegerin in Patients with Calcified Aortic Valve Stenosis in Relation to Heart Failure." Acta clinica Croatica 56, br. 4 (2017): 733-741. https://doi.org/10.20471/acc.2017.56.04.22
Harvard
Makarović, S., et al. (2017). 'Serum Osteoprotegerin in Patients with Calcified Aortic Valve Stenosis in Relation to Heart Failure', Acta clinica Croatica, 56(4), str. 733-741. https://doi.org/10.20471/acc.2017.56.04.22
Vancouver
Makarović S, Makarović Z, Bilić-Ćurčić I, Milas-Ahić J, Mihaljević I, Franceschi M i sur. Serum Osteoprotegerin in Patients with Calcified Aortic Valve Stenosis in Relation to Heart Failure. Acta clinica Croatica [Internet]. 2017 [pristupljeno 27.11.2020.];56(4):733-741. https://doi.org/10.20471/acc.2017.56.04.22
IEEE
S. Makarović, et al., "Serum Osteoprotegerin in Patients with Calcified Aortic Valve Stenosis in Relation to Heart Failure", Acta clinica Croatica, vol.56, br. 4, str. 733-741, 2017. [Online]. https://doi.org/10.20471/acc.2017.56.04.22

Sažetak
The aim of the study was to assess the role of serum osteoprotegerin (OPG) as a biomarker in patients with aortic valve stenosis (AS) in relation to heart failure and symptomatic status. This was a case control study, which included 51 patients with AS and 39 control subjects. At the time of study enrolment, detailed medical history was obtained and all subjects underwent physical examination, chest x-ray and echocardiography. OPG levels were measured in all subjects, and serum N-terminal of the pro b-type natriuretic peptide (NT pro BNP) levels were determined in patients with AS. Serum OPG levels were elevated in patients with AS compared to control subjects (p=0.001). Pa-tients with heart failure due to AS had elevated serum OPG levels in comparison to patients without heart failure (p=0.001). A significant correlation between OPG and symptomatic status was observed in all patients with AS (p<0.001), however, it was not the case in patients without heart failure (p=0.425). There was a positive correlation between OPG and NT pro BNP concentrations with objective signs of heart failure on chest x-ray (p<0.001). Negative correlation of OPG concentrations with aortic valve area was present (p<0.040), as well as with left ventricular ejection fraction (p<0.001). Serum OPG could be a valuable biomarker in the evaluation of severity of calcified AS and serve as an additional indicator besides clinical presentation and echocardiography in the assessment of surgical treatment or aortic valve replacement.

Ključne riječi
Osteoprotegerin – blood; Aortic valve stenosis – pathology; Calcinosis – blood; Heart failure; Biomarkers – blood; Natriuretic peptides

Hrčak ID: 195471

URI
https://hrcak.srce.hr/195471

[hrvatski]

Posjeta: 471 *